---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-092604"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2026-08-21T20:15:14+00:00"
generated_at: "2026-08-21T20:16:17.886307+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma gets Nasdaq bid-price compliance extension to Feb 8, 2027

## Summary
- Nasdaq granted extension to Feb 8, 2027 to regain compliance with $1.00 bid price rule.
- Must close at or above $1.00 for 10 consecutive business days before deadline.
- Failure to comply by Feb 8, 2027 triggers delisting notice; company may appeal.
- Stock remains listed on Nasdaq Capital Market under CTXR; no immediate effect.
- Company evaluating options; no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001213900-26-092604
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2026-08-21T20:15:14+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390026092604/0001213900-26-092604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390026092604/ea0302856-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-092604
- JSON: https://secwatch.observer/filing/0001213900-26-092604.json
- Plain text: https://secwatch.observer/filing/0001213900-26-092604.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.